Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study.
The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year.
The drug significantly improved memory and other factors in patients when compared to a placebo, and more details about the study will be released in November.
The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the.
The drug significantly improved memory and other factors in patients when compared to a placebo, and more details about the study will be released in November.